Newsbenzinga
Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline
· Published
Article summary
Novartis shares rise as strong Q2 demand for key growth drugs offsets generic competition. NVS beats Q2 earnings and reaffirms 2026 targets.
An excerpt from the original article.
Comments —
Loading comments…